Elanco scores USDA nod for new canine allergy drug Befrena
Elanco expects Befrena to launch in the US in the first half of 2026
Elanco expects Befrena to launch in the US in the first half of 2026
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The plant is expected to enhance regional supply capabilities
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated